Efficacy and safety of tamsulosin in prevention of post-operative urinary retention in hip fracture: a randomized double-blind placebo-controlled study

AIIMS Bhubaneswar0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年6月27日

试验速览

暂无简介。

•1.History of neurogenic bladder or urological problems requiring routine intermittent catheterization
•2.Patients unable to take an oral medication
•3.Patient who would require an indwelling catheter for other reasons, or patients who needed catheterisation during admission to the emergency for voiding difficulty
•4.Patients with systolic blood pressure <100 mmhg or orthostatic hypotension
•5.Pregnant women
•6.Associate trauma of spine or pelvis
•7.Patients taking medications for lower urinary tract symptoms or who had previously undergone prostatectomy
•8.Patients with severe liver or kidney disease
•9.Patients taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir/ritonavir, lopinavir/ritonavir, or conivaptan), use of a 5-alpha reductase inhibitor medication, the use of sildenafil, tadalafil, or vardenafil, history of an allergy or sensitivity to tamsulosin or other alpha-blockers (alfuzosin, doxazosin, prazosin,
•Terazosin, or phenoxybenzamine),
•10.Uncontrolled concomitant illness including, but not limited to, ongoing or active infection
•11.Congestive heart failure, unstable angina pectoris, cardiac arrhythmia,
•12.Psychiatric illness

发起方